Scott Requadt is the founder of Prolium. Prolium has raised $50M in total funding. Latest round: Series A. Backed by RTW Investments. Based in New York, NY.
Scott Requadt is the CEO of Prolium Bioscience, a clinical stage biotechnology company based in NYC. Prolium Bioscience is developing PRO-203, a potential bispecific CD20xCD3 antibody for systemic sclerosis and other severe autoimmune diseases. The company recently raised $50M in Series A funding, led by RTW Investments.
Full founder directory · Investor directory · Company funding database · Fundraising library